DEVELOPMENT OF TUMOR MODELS FOR PRECLINICAL INVESTIGATION OF THE NEW TARGET DRUGS AGAINST <i>HER2/NEU</i>
<i>HER2/neu </i>is the one from epidermal growth factor receptors family, which plays the important role in the etiology and pathogenesis of different kind of tumors. The most important significance this receptor has for the breast and ovarian cancer. The drug Herceptin, which are blocking this receptor, has been used at the clinical practice by the patients with breast cancer. The development of the new effective and chip drugs against <i>HER2/neu </i>are perspective now. For testing of these drugs is necessary to have adequate tumor models <i>in vivo. </i>The purpose of this investigation was to receive the tumor models positive of <i>HER2/neu </i>on immunodeficient mice for the preclinical evaluation <i>in vivo </i>of the new drugs against <i>HER2/neu. </i>There are presented the results of subcutaneous transplantation of two human cell lines of breast cancer SKBR3 and ovarian SKOV3 to the mice <i>Balb/c nude </i>breaded in Blokhin Russian Cancer Research Center. So presented the results of <i>HER2/neu </i>testing in the tumor passages <i>in vivo.</i>